Dupilumab (Dupixent) for severe eczema in infants
To find out safety and effectiveness of dupilumab (Dupixent) in infants with severe eczema.
To find out safety and effectiveness of dupilumab (Dupixent) in infants with severe eczema.
To understand how environmental factors affect a child's early brain development. This includes positive factors like social support and parent-child bonding and challenges like poverty, stress and early life exposures.
1) To determine if 5 doses of Epo (Erythropoietin) 1000 U/kg (birth weight) intravenous (IV) reduces the rate of death or neurodevelopmental impairment (mild, moderate, or severe) at 24 months of age.
2) To assess safety of Epo.
3) To determine whether Epo decreases the severity of HIE-induced brain injury as evidenced by early MRI and plasma biomarkers of brain injury.